Pasithea Therapeutics Azioni (NASDAQ: KTTA)

Ultime notizie per Pasithea Therapeutics (NASDAQ:KTTA) Azioni

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

WIIM

Alliant Energy shares are trading lower. The company reported Q3 financial results.

Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/quote/GNRC/earnings">fourth quarter on Thursday</a>.
The company posted quarterly earnings of $2.25 per share which beat the analyst consensus estimate of $1.95 per share. The company reported quarterly sales of $1.173 billion which beat the analyst consensus estimate of $1.161 billion.
&#8220;Our third quarter results outperformed our expectations as elevated power outage activity drove increased shipments of our residential products and strong execution helped to deliver significant margin expansion,&#8221; said Aaron Jagdfeld, President and Chief Executive Officer. &#8220;Shipments of home standby and portable generators increased at a very strong rate from the prior year period, more than offsetting expected softness in C&amp;I product sales. As a result, we are updating our full year 2024 guidance to include higher residential product sales with further improvements in adjusted EBITDA margins.&#8221;
Generac shares gained 2.4% to trade at $169.47 on Friday.
These analysts made changes to their price targets on Generac following earnings announcement.
<ul>
<li>Baird analyst Michael Halloran maintained Generac with a Neutral and lowered the price target from $187 to $181.</li>
<li>Goldman Sachs analyst Jerry Revich maintained the stock with a Buy and raised the price target from $148 to $193.</li>
<li>TD Cowen analyst Jeffrey Osborne maintained Generac with a Buy and raised the price target from $172 to $183.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Earnings

News

Price Target

Markets

Analyst Ratings

GNRC

These Analysts Revise Their Forecasts On Generac After Q4 Results

Wells Fargo analyst Michael Turrin maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Equal-Weight and raises the price target from $75 to $80.

TWLO

Wells Fargo Maintains Equal-Weight on Twilio, Raises Price Target to $80

PCTY

Paylocity Holding shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $195 to $210.

On Thursday,&nbsp;Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/earnings-beats/24/10/41655506/merck-beats-q3-estimates-but-lowers-annual-forecast-as-gardasil-vaccine-hit-by-low-c" rel="noreferrer noopener">consensus of $16.47 billion</a>.
Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., due to lower demand in China, partially offset by higher sales in the U.S., driven by public-sector buying patterns, higher pricing and demand, and higher demand in most international regions.
Beyond Gardasil, Goldman Sachs highlights a solid lineup of positives for Merck, including robust performance from key franchises like Keytruda and promising momentum from both commercial products like Winrevair and Capvaxive and development-stage innovations such as clesrovimab and tulisokobart.
Merck's blockbuster cancer immunotherapy Keytruda generated&nbsp;$7.43 billion&nbsp;in revenue during the quarter, up 17% from the year-earlier period.&nbsp;
The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958211/mercks-11b-bet-pays-as-fda-approves-sotatercept-for-rare-lung-disease" rel="noreferrer noopener">sales of $149 million</a>.
Goldman reiterates the Buy rating for Merck stock, decreasing the price target from $139 to $135, reflecting lowered <a target="_blank" href="https://www.benzinga.com/quote/MRK/analyst-ratings" rel="noreferrer noopener">resetting of Gardasil forecasts</a>.
BMO Capital Markets suggests that Merck's Gardasil sales in China may continue to be challenging through 2025.
Although Merck does not provide specific product-level forecasts, CEO Rob Davis offered some perspective, anticipating Gardasil sales in China could reach around $2 billion to $3 billion in 2025.
Winrevair continues to show strong performance, driven by organic demand. According to a BMO analyst, there was some initial skepticism about the organic demand for Winrevair after comments regarding stocking in Q2 2024.
However, the recent performance data has restored confidence, indicating that the drug is experiencing sustained demand growth, with an uptake of approximately 80% for the quarter.
This trend is expected to continue into 2025, particularly with the forthcoming ZENITH and CADENCE trials.
BMO cut the price target from $150 to $136, with an Outperform rating.
Price Action: MRK stock is down 0.22% at $102.07&nbsp;at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41689161/wayfair-q3-results-earnings-beat-street-but-sales-and-customer-base-decline" target="_blank" rel="noreferrer noopener">Wayfair Q3 Results: Earnings Beat Street, But Sales And Customer Base Decline</a></li>
</ul>
Image via Merck

Analyst Color

Biotech

Large Cap

Health Care

Trading Ideas

General

Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease

TD Cowen analyst Jeffrey Osborne maintains Nikola (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) with a Hold and lowers the price target from $10 to $4.

NKLA

TD Cowen Maintains Hold on Nikola, Lowers Price Target to $4

Wells Fargo analyst Ken Gawrelski maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Underweight and lowers the price target from $47 to $44.

ETSY

Wells Fargo Maintains Underweight on Etsy, Lowers Price Target to $44

LECO

Lincoln Electric shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

TD Cowen analyst Jeffrey Osborne maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Buy and lowers the price target from $95 to $74.

APTV

TD Cowen Maintains Buy on Aptiv, Lowers Price Target to $74

Imperial Oil shares are trading lower after the company reported mixed Q3 financial results.

CTRA

Corterra Energy shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results and cut its FY24 capital expenditure.

B of A Securities analyst Bryan Spillane maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and lowers the price target from $100 to $75.

B of A Securities Maintains Neutral on Estee Lauder Cos, Lowers Price Target to $75

UBS analyst Jay Sole maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Buy and raises the price target from $103 to $110.

UBS Maintains Buy on Kontoor Brands, Raises Price Target to $110

Dayforce shares are trading higher after BMO Capital maintained an Outperform rating on the stock and raised its price target from $70 to $80.

Service Corp International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) reported better-than-expected third-quarter adjusted <a href="https://www.benzinga.com/quote/SCI/earnings">EPS results on Thursday</a>.
Service Corp Intl reported quarterly earnings of 79 cents per share beat the analyst consensus estimate of 77 cents per shsare. The company reported quarterly sales of $1.014 billion which missed the analyst consensus estimate of $1.016 billion.
Tom Ryan, the Company&#8217;s Chairman and CEO, commented, &#8220;Today we reported adjusted earnings per share of $0.79 and net cash provided by operating activities excluding special items of $269 million. We are excited to see the positive impact in funeral revenue from our new marketing agreement with our new preferred preneed insurance provider, which launched during the quarter. Additionally, we are pleased both funeral and cemetery gross profit were relatively stable versus the prior year third quarter with modest revenue growth reflecting our continued focus on managing fixed costs.&#8221;
Service Corp Intl said it sees fourth-quarter adjusted loss of $1.00-1.10 per share, versus estimates of 77 cents per share.
Service Corp International shares gained 0.2% to trade at $81.79 on Friday.
These analysts made changes to their price targets on Service Corp International following earnings announcement.
<ul>
<li>Raymond James analyst John Ransom maintained Service Corp Intl with an Outperform and increased the price target from $80 to $85.</li>
<li>Truist Securities analyst Tobey Sommer maintained the stock with a Buy and raised the price target from $84 to $92.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Service Corp International Analysts Boost Their Forecasts After Upbeat Earnings

TD Cowen analyst Jeffrey Osborne maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Buy and raises the price target from $172 to $183.

TD Cowen Maintains Buy on Generac Hldgs, Raises Price Target to $183

UBS analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $411 to $441.

MDGL

UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $441

TD Cowen analyst Jeffrey Osborne maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $136.

ITRI

TD Cowen Maintains Buy on Itron, Raises Price Target to $136

Craig-Hallum analyst Anthony Stoss maintains Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) with a Buy and lowers the price target from $96 to $90.

SIMO

Craig-Hallum Maintains Buy on Silicon Motion Technology, Lowers Price Target to $90

On Thursday,&nbsp;Bristol Myers Squibb &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;posted third-quarter revenues of $11.89 billion, beating the consensus of $11.28 billion, an increase of 8% year-over-year, or 10% when adjusted for foreign exchange impacts, primarily driven by the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">Growth Portfolio and&nbsp;Eliquis</a>.
Growth Portfolio worldwide revenues increased to $5.81 billion compared to $4.95&nbsp;billion a year ago, representing growth of 18% on a reported basis or 20% when adjusted for&nbsp;foreign exchange impacts.
BMO Capital Markets appreciates a conservative approach in the neuropsych space, though it notes management&#8217;s reserved stance on revenue expectations. It highlights that significant revenue is not expected until the second half of 2025, with a gradual launch anticipated for schizophrenia treatment.
The analyst considers the potential for Alzheimer&#8217;s psychosis treatment as an added upside, likely to positively impact sentiment.
While Bristol-Myers Squibb&#8217;s recent quarterly performance showed encouraging progress in top-line growth and cost management, its true transformation will stem from its pipeline, the BMO analyst writes.
The recent approval of Cobenfy, along with newly launched growth products, could bring the momentum investors have been anticipating.
Truist analysts noted that much of the Q3 earnings call centered on KarXT (Cobenfy), a critical asset for treating schizophrenia that could drive significant revenue and support long-term growth.
Truist analyst projects global peak sales at $4.2 billion, below the $5.4 billion consensus estimate.
While business development and partnerships are crucial to diversifying the company&#8217;s portfolio and strengthening its long-term outlook, Truist emphasized that maintaining dividends and reducing debt remain top priorities.
Price Action: BMY stock is down 1.91% at $54.71 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41686173/cancer-focused-essa-pharma-ends-prostate-cancer-trial-due-to-insufficient-efficacy-from-combinati" target="_blank" rel="noreferrer noopener">Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy</a></li>
</ul>
Image: Wikimedia Commons

Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ReShape Lifesciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for <a href="https://finance.yahoo.com/news/reshape-lifesciences-receives-fda-pma-210500500.html">a PMA supplement</a>.



That a PMA supplement applies to the company&rsquo;s Lap-Band 2.0 FLEX. This is the company&rsquo;s minimally invasive, long-term treatment of obesity.



Paul Hickey, president and CEO of ReShape Lifesciences, explains the differences the come with its updated Lap-Band 2.0 FLEX product.




&ldquo;Compared to our current Lap-Band, the Lap-Band&reg; 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage (or stoma), created by the band. Specifically, the band momentarily relaxes before returning to its resting diameter, therefore, minimizing discomfort caused by passage of large food pieces through the stoma.&rdquo;




<h2>What This Means for RSLS Stock</h2>



Improvement of its weight loss product is a positive for ReShape Lifesciences. The FDA approval also allows puts it closer to market, which could mean more revenue for the company.



With this news comes heavy trading of RSLS stock. As of this writing, around 50 million shares have changed hands. That&rsquo;s a massive leap in trading volume compared to the company&rsquo;s daily average of about 4 million shares.



RSLS stock is up 67.7% as of Wednesday morning.



There&rsquo;s more stock market news worth reading about below!



We have all of the hottest stock market news traders need to know about on Wednesday! Among that is what&rsquo;s happening with shares of Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>), Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>)&nbsp;and Innovative International&nbsp;Acquisition&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ioac-stock-quote/">IOAC</a>) stock. You can find out more on these matters down below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-innovative-international-ioac-stock-up-31-today/">Why Is Innovative International (IOAC) Stock Up 31% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Palantir Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock is in the news Wednesday after the big data company <a href="https://finance.yahoo.com/news/palantir-renews-digital-transformation-partnership-115900977.html">renewed a contract</a> with UniCredit.



According to a press release from Palantir, UniCredit has renewed its partnership with the company for another five years. That will see it make use of the Palantir Foundry operating system to enhance its digital transformation.



Investors will note that Palantir and UniCredit first started working together in 2018. Over those five years, UniCredit saw significant benefits from the Palantir Foundry operating system. That even resulted in it expanding the use of the technology to all CE&amp;EE UniCredit Legal Entities.



Josh Harris, a Palantir executive, said the following about this partnership.




&ldquo;Palantir has long been a proud partner to some of the world&rsquo;s top financial institutions. We&rsquo;re honored that UniCredit has placed its confidence in Palantir once again and look forward to furthering the bank&rsquo;s digital transformation.&rdquo;




<h2>PLTR Stock Movement on Wednesday</h2>



With this recent news comes some 7 million shares of PLTR stock changing hands. That&rsquo;s still a ways off from its daily average trading volume of about 61 million shares. The stock is also down 1.3% as of Wednesday morning despite the renewed contract. However, PLTR is up 170.4% year-to-date.



Investors looking for more of the latest stock market news will want to keep reading!



We have all of the hottest stock market news worth checking out on Wednesday! A few examples of that include what&rsquo;s happening with ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>), Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) and Loop Media&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/">LPTV</a>) stock. You can find more on these matters below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-loop-media-lptv-stock-down-16-today/">Why Is Loop Media (LPTV) Stock Down 16% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PLTR Stock: Palantir Renews UniCredit Partnership

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Roblox (NYSE:<a href="https://investorplace.com/stock-quotes/rblx-stock-quote/">RBLX</a>) stock is on the move Wednesday as investors react to new coverage of the video game company&rsquo;s shares from Wells Fargo.



Wells Fargo analysts <a href="https://www.investing.com/news/stock-market-news/roblox-ads-to-become-significant-earnings-stream-over-time--wells-fargo-432SI-3255780">initiated coverage of RBLX stock</a> with an &ldquo;overweight&rdquo; rating. To put that in perspective, the analysts&rsquo; consensus rating for RBLX shares is moderate buy based on 22 opinions.



In addition to that, the company started its coverage of RBLX stock with a price target of $49 per share. That represents a potential upside of 16.6%. It&rsquo;s also bullish next to the analysts&rsquo; consensus price prediction of <a href="https://www.marketbeat.com/stocks/NYSE/RBLX/price-target/">$41.62 per share</a>.



<h2>Why the Bull Rating for RBLX Stock?</h2>



Here&rsquo;s what the Wells Fargo analysts had to say about Roblox in a note to clients obtained by Investing.com.




&ldquo;Similar to other audience platforms, we expect ads to become a significant earnings stream over time for Roblox, supported by strong user engagement. See meaningful upside to consensus bookings and EBITDA as we believe the ads opportunity is underappreciated by the Street, which has yet to properly capture future ad bookings into forecasts.&rdquo;




RBLX stock is up 2.5% as of Wednesday morning. This comes with more than 3.8 million shares traded. For the record, the company&rsquo;s daily average trading volume is still above that at 10.5 million shares.



Investors who want more of the latest stock market news are in luck!



We&rsquo;ve got all of the hottest stock market stories that traders need to know about on Wednesday! That includes everything going on with Palantir Technologies&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>) stock, ReShape Lifesciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rsls-stock-quote/">RSLS</a>) stock and Pasithea Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) stock. You can find out more on these matters at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/12/pltr-stock-palantir-renews-unicredit-partnership/">PLTR Stock: Palantir Renews UniCredit Partnership</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-reshape-lifesciences-rsls-stock-up-68-today/">Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?</a></li>



<li><a href="https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/">Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2023/12/rblx-stock-alert-wells-fargo-initiates-roblox-coverage-with-overweight-rating/">RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With &#8216;Overweight&#8217; Rating</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RBLX Stock Alert: Wells Fargo Initiates Roblox Coverage With 'Overweight' Rating

Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares on the final day of trading this week!



Moving stocks today are public offerings, an earnings report and more.



Let&rsquo;s dive into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Aclarion (NASDAQ:<a href="https://investorplace.com/stock-quotes/acon-stock-quote/">ACON</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Himalaya Shipping (NYSE:<a href="https://investorplace.com/stock-quotes/hshp-stock-quote/">HSHP</a>) shares are soaring over 21% without any clear news this morning.</li>



<li>Ekso Bionics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ekso-stock-quote/">EKSO</a>) stock is surging more than 20% with strong early morning trading.</li>



<li>Panbela Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbla-stock-quote/">PBLA</a>) shares are gaining over 19% as it prepares for a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318006293&amp;type=PDF&amp;symbol=PBLA&amp;cdn=255e23064a07775ab2cefc841a6dd3b1&amp;companyName=Panbela+Therapeutics+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-01-25">proposed public offering</a>.</li>



<li>Ucommune International (NASDAQ:<a href="https://investorplace.com/stock-quotes/uk-stock-quote/">UK</a>) stock is increasing more than 18% on Friday morning.</li>



<li>The Real Brokerage (NASDAQ:<a href="https://investorplace.com/stock-quotes/reax-stock-quote/">REAX</a>) shares are rising over 18% after <a href="https://www.nasdaq.com/press-release/the-real-brokerage-invites-you-to-join-us-at-the-microcap-conference-2024-01-25">announcing a presentation next week</a>.</li>



<li>BIT Mining Limited (NYSE:<a href="https://investorplace.com/stock-quotes/btcm-stock-quote/">BTCM</a>) stock is climbing more than 16% on Friday.</li>



<li>Lixiang Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxeh-stock-quote/">LXEH</a>) shares are getting an over 15% boost after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318005286&amp;type=PDF&amp;symbol=LXEH&amp;cdn=6639882602bf7fce8ca884d95ec782b1&amp;companyName=Lixiang+Education+Holding+Co.+Ltd.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-01-25">regaining Nasdaq compliance</a>.</li>



<li>Porch Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/prch-stock-quote/">PRCH</a>) stock is jumping more than 14% <a href="https://www.nasdaq.com/press-release/porch-group-receives-%2425m-with-signing-of-strategic-agreement-with-aon-2024-01-25">alongside a strategic agreement</a>.</li>



<li>Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Aptose Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/apto-stock-quote/">APTO</a>) stock is plummeting more than 26% as <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318008758&amp;type=PDF&amp;symbol=APTO&amp;cdn=12b3da5a3896f2a507db32324ce6eb5a&amp;companyName=Aptose+Biosciences+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-01-25">a public offering goes into effect</a>.</li>



<li>SU Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) shares are diving over 21% following its recent <a href="https://www.nasdaq.com/press-release/su-group-holdings-limited-announces-pricing-of-initial-public-offering-2024-01-23">initial public offering (IPO)</a>.</li>



<li>Eve&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/evex-stock-quote/">EVEX</a>) stock is tumbling more than 19% despite a lack of news.</li>



<li>Paramount Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/para-stock-quote/">PARA</a>) shares are retreating over 18% after <a href="https://investorplace.com/2024/01/para-stock-alert-is-david-ellison-about-to-take-paramount-global-private/">rising yesterday on acquisition reports</a>.</li>



<li>LAVA Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lvtx-stock-quote/">LVTX</a>) stock is taking a more than 12% beating <a href="https://www.marketwatch.com/story/lava-therapeutics-shares-rise-as-drug-set-for-test-with-merck-s-keytruda-c936d7cd">after rallying yesterday</a>.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) shares are dropping over 12% after <a href="https://www.nasdaq.com/press-release/nxu-submits-for-nevi-grant-funding-to-enhance-its-major-highway-electrification-goals">seeking new grant funding</a>.</li>



<li>Sagimet Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgmt-stock-quote/">SGMT</a>) stock is decreasing more than 11% with <a href="https://finance.yahoo.com/news/sagimet-biosciences-announces-proposed-public-224500288.html">public offering plans</a>.</li>



<li>Integrated Media Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/imte-stock-quote/">IMTE</a>) shares are falling over 11% on Friday.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is sliding more than 10% with <a href="https://www.cnbc.com/2024/01/25/intel-intc-earnings-report-q4-2023.html">Q4 earnings results</a>.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/01/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the first quarter of 2024.<ul><li>Pasithea Therapeutics reported earnings per share of -$3.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ktta-stock-earnings-pasithea-therapeutics-for-q1-of-2024/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the fourth quarter of 2023.<ul><li>Pasithea Therapeutics reported earnings per share of -$4.10.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/ktta-stock-earnings-pasithea-therapeutics-for-q4-of-2023/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pasithea Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktta-stock-quote/">KTTA</a>) just reported results for the second quarter of 2024.<ul><li>Pasithea Therapeutics reported earnings per share of -$3.71.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ktta-stock-earnings-pasithea-therapeutics-for-q2-of-2024/">KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q2 2024

Pasithea Therapeutics drops 19% on $5M private placement

Pasithea Therapeutics files to sell 3.74M shares of common stock for holders

ACON

APTO

BTCM

CMND

EKSO

EVEX

HSHP

IMTE

INTC

IOAC

KTTA

KTTAW

LPTV

LVTX

LXEH

PARA

PBLA

PLTR

PRCH

RBLX

REAX

RSLS

SGMT

SUGP

Press Releases

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Comments

Pasithea Therapeutics

Notizie

Ultime notizie per Pasithea Therapeutics (NASDAQ:KTTA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO